Key result
The provided text contains only the editorial board and publisher information for the journal, with no clinical data or results available for extraction.
Why the study?
Does acarbose 100 mg t.i.d improve forearm blood flow in newly diagnosed type 2 diabetic patients?
Population
20 newly diagnosed type 2 diabetic patients and 10 healthy control subjects
Comparison
Acarbose 100 mg t.i.d for 20 weeks vs Matching placebo
Design
RCT, randomly assigned, placebo-controlled
Follow-up
20 weeks
Authors
Loading...
Acarbose does not improve endothelial dysfunction in new type 2 diabetes; challenges vascular benefit hypotheses and reinforces glycemic control as primary goal.
Does acarbose 100 mg t.i.d improve forearm blood flow in newly diagnosed type 2 diabetic patients?
Acarbose treatment for 20 weeks does not improve fasting or postprandial endothelial dysfunction in newly diagnosed type 2 diabetes.
Pistrosch et al. (2008) studied Type 2 Diabetes. Acarbose was evaluated on Endothelial function after a mixed meal. The provided text contains only the editorial board and publisher information for the journal, with no clinical data or results available for extraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: